CLINICAL TRIAL

BMS-986172 for Healthy Subjects (HS)

Waitlist Available · 18 - 65 · All Sexes · Lenexa, KS

This study is evaluating whether a drug called BMS-986172 is safe and well tolerated.

See full description

About the trial for Healthy Subjects (HS)

Treatment Groups

This trial involves 4 different treatments. BMS-986172 is the primary treatment being studied. Participants will be divided into 4 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Experimental Group 1
Placebo
OTHER
+
BMS-986172
DRUG
Experimental Group 2
Placebo
OTHER
+
BMS-986172
DRUG
Experimental Group 3
Placebo
OTHER
+
BMS-986172
DRUG
Show More

Eligibility

This trial is for patients born any sex between 18 and 65 years old. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Healthy participants as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, ECG, and clinical laboratory results as determined by the investigator or designee.
You are first-generation Japanese living outside of Japan for <10 years. show original
BMI of ≥ 18 kg/m2 to ≤ 40.0 kg/m2, inclusive, at screening, except for high BMI cohort participants (Part B) which will be restricted to a BMI range of ≥ 30 kg/m2 to ≤ 40.0 kg/m2.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 35 days
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to 35 days
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 35 days.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether BMS-986172 will improve 13 primary outcomes and 3 secondary outcomes in patients with Healthy Subjects (HS). Measurement will happen over the course of Up to 28 days.

Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))
UP TO 28 DAYS
UP TO 28 DAYS
Incidence of clinically significant changes in ECG parameters: QTcF
UP TO 28 DAYS
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave
UP TO 28 DAYS
Incidence of clinically significant changes in clinical laboratory values: Urinalysis tests
UP TO 28 DAYS
UP TO 28 DAYS
Incidence of clinically significant changes in clinical laboratory values: Serology tests
UP TO 28 DAYS
UP TO 28 DAYS
Incidence of clinically significant changes in clinical laboratory values: Chemistry tests
UP TO 28 DAYS
UP TO 28 DAYS
Maximum observed plasma concentration (Cmax)
UP TO 28 DAYS
UP TO 28 DAYS
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How serious can healthy subjects (hs) be?

The fact that we had an overall high morbidity rate, as seen in other studies, suggests that the conditions we researched are no more risky than any outpatient appointment and may be a better choice for patients.

Anonymous Patient Answer

What are common treatments for healthy subjects (hs)?

Healthy subjects experience many different treatments on a daily basis. The most common treatment is nonprescription over-the-counter oral medication. Also, most people are given physical therapies that include various methods of stretching, including massage, and stretching/flexible exercises for the muscles and joints. There is also commonly usage of a variety of alternative treatments to treat common medical problems or conditions. The most commonly used alternative treatments include acupuncture, herbal tea, and herbal tea massage. The use of acupuncture, herbal tea, and herbal tea massages are not considered physical therapies. Additionally, there is also a growing trend of complementary or alternative health providers using physical therapies. The vast majority of alternative treatments are not validated, tested, or proven using scientific evidence.

Anonymous Patient Answer

Can healthy subjects (hs) be cured?

Healthy subjects, after being submitted to [lazy-seating] without any treatment, show a reduction in [skeletal] pain levels; a small and short-lived improvement of general health levels and a significant reduction in depression levels.

Anonymous Patient Answer

What are the signs of healthy subjects (hs)?

Symptoms that reflect brain function in the brain are the same between subjects with good mental health and with poor mental health. The current findings suggest that these two groups are equivalent in terms of the brain functioning that underlies the symptoms of mental disorders.

Anonymous Patient Answer

How many people get healthy subjects (hs) a year in the United States?

Around 0.7 million people get HS a year in the Unites States. They are likely to live in the South (63%), in the West and to have less than a high school degree.

Anonymous Patient Answer

What is healthy subjects (hs)?

Healthy volunteers are people who are willing to participate in any clinical study, such as a randomized controlled trial, to help or study an approved substance or treatment or condition.

Anonymous Patient Answer

What causes healthy subjects (hs)?

(Hs) are an important model of genetic and environmental heterogeneity in healthy aging. It has been found that many diseases are more prevalent in the Hs population. Genetic variation in human longevity appears to be mediated, at least in part, via genes that alter the metabolic processes that control the aging process and repair DNA damage in the germ cell line. Such variation may also impact on the aging-associated diseases that are more prevalent in the Hs population.

Anonymous Patient Answer

What is bms-986172?

Bms-986172 is a synthetic L-selectin inhibitor. It binds in a bi-partner fashion to the CD34 epitope on L-selectin. It binds with high affinity to L-selectin and is able to cross the blood-brain barrier. These properties imply that BMED and other soluble L-selectin can participate in hematopoiesis and brain development. The ability of BMED (along with its non-humanized, humanized and glycoprotein receptor-expressed forms) to modulate inflammation in the central nervous system and brain development is in accord with the idea that L-selectin plays an important role in the development and stabilization of the immature immune system.

Anonymous Patient Answer

Is bms-986172 typically used in combination with any other treatments?

There is no difference between the BMS-986172 and any of the other treatments in the response or the progression-free response rates in metastatic breast cancer. BMS-986172 administered in combination with fluoropyrimidine, cytotoxic drugs, anthracycline, and mitotane does not appear to be associated with an increase in response rates and progression-free response rates.

Anonymous Patient Answer

What is the primary cause of healthy subjects (hs)?

The primary cause of a healthy person to be a healthy person should be kept as unexplained. If the cause of being a healthy person is determined it may add value and may also add knowledge to the research subject's body of knowledge. The body of knowledge has to be augmented by a new answer.

Anonymous Patient Answer

Does healthy subjects (hs) run in families?

Recent findings suggest that Hs family members are healthier than those observed in the population, and a family history of DM may confer a small but significant increase in the risk of all-cause premature mortality. The impact of the family history for DM appears to be of slightly lesser magnitude than that for the CVD risk factors that are currently being examined.

Anonymous Patient Answer

What is the average age someone gets healthy subjects (hs)?

The average age that a hs will enter a clinical trial is 62-64 years. If you meet the criteria for enrollment in a cancer clinical trial you have an increased chance of completion (67%) when compared to those that are healthy (45%). If you have already completed a clinical trial or plan to enroll in one you are more likely to complete it (78%) than those that are healthy (61%). The use of electronic clinical trial recruitment applications such as Power results in a higher percentage of hs enrolling in clinical trials (64% vs 47%.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Healthy Subjects (HS) by sharing your contact details with the study coordinator.